Linked Life Data

16039648

Source:http://linkedlifedata.com/resource/pubmed/id/16039648

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-2
pubmed:dateCreated
2005-9-5
pubmed:abstractText
Effect of 3-(2,4-dichlorobenzyl)-2-methyl-N-(pentylsulfonyl)-3H-benzimidazole-5-carboxamide (FK614), a novel nonthiazolidinedione peroxisome proliferator-activated receptor (PPAR) gamma agonist, on glucose tolerance and insulin resistance in peripheral tissues and in liver using Zucker fatty rats (genetically obese and insulin-resistant) was evaluated and compared to other insulin sensitizers. FK614 (0.32, 1 and 3.2 mg/kg), two thiazolidinedione PPAR gamma agonists, rosiglitazone (0.1, 0.32, 1 and 3.2 mg/kg) and pioglitazone (1, 3.2 and 10 mg/kg), and a biguanide, metformin (320 and 1000 mg/kg), were orally administered to Zucker fatty rats once a day for 14 days. Zucker fatty rats treated with FK614 and rosiglitazone were subjected to evaluation by oral glucose tolerance test. Ameliorating effect of each compound on peripheral and hepatic insulin resistance was evaluated using a euglycemic-hyperinsulineamic clamp procedure. FK614 and rosiglitazone dose-dependently improved impaired glucose tolerance in Zucker fatty rats. In addition, FK614 dose-dependently ameliorated peripheral and hepatic insulin resistance in Zucker fatty rats, with the degree of its effect in peripheral tissues almost equivalent to that in liver when compared at each dose tested. Similar data indicating ameliorating effects on insulin resistance was obtained for rosiglitazone and pioglitazone. Metformin showed less potent effects than other insulin sensitizers and its effect in liver tended to be greater than that in peripheral tissues. These findings suggest clinical potential for FK614 as a treatment of type 2 diabetes, acting by ameliorating insulin resistance both in peripheral tissues and liver.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0014-2999
pubmed:author
pubmed:issnType
Print
pubmed:day
5
pubmed:volume
519
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
182-90
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:16039648-Administration, Oral, pubmed-meshheading:16039648-Animals, pubmed-meshheading:16039648-Benzimidazoles, pubmed-meshheading:16039648-Blood Glucose, pubmed-meshheading:16039648-Dose-Response Relationship, Drug, pubmed-meshheading:16039648-Glucose, pubmed-meshheading:16039648-Glucose Intolerance, pubmed-meshheading:16039648-Glucose Tolerance Test, pubmed-meshheading:16039648-Hypoglycemic Agents, pubmed-meshheading:16039648-Insulin, pubmed-meshheading:16039648-Insulin Resistance, pubmed-meshheading:16039648-Liver, pubmed-meshheading:16039648-Male, pubmed-meshheading:16039648-Metformin, pubmed-meshheading:16039648-PPAR gamma, pubmed-meshheading:16039648-Rats, pubmed-meshheading:16039648-Rats, Zucker, pubmed-meshheading:16039648-Thiazolidinediones, pubmed-meshheading:16039648-Time Factors
pubmed:year
2005
pubmed:articleTitle
Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.
pubmed:affiliation
Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., 1-6, Kashima 2 chome, Osaka 532-8514, Japan. hideaki.minoura@jp.astellas.com
pubmed:publicationType
Journal Article, Comparative Study